Cargando…
Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy
BACKGROUND: The aim of the study was to evaluate the independent prognostic role of PIK3CA activating mutations and an association between PIK3CA activating mutations and efficacy of adjuvant endocrine therapy (ET) in patients with operable invasive lobular carcinoma (ILC). PATIENTS AND METHODS: A s...
Autores principales: | Ribnikar, Domen, Horvat, Valentina Jeric, Ratosa, Ivica, Veitch, Zachary W, Grcar Kuzmanov, Biljana, Novakovic, Srdjan, Langerholc, Erik, Amir, Eitan, Seruga, Bostjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286895/ https://www.ncbi.nlm.nih.gov/pubmed/37341201 http://dx.doi.org/10.2478/raon-2023-0027 |
Ejemplares similares
-
BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome
por: Blatnik, Ana, et al.
Publicado: (2022) -
Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade
por: Ribnikar, Domen, et al.
Publicado: (2021) -
Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
por: Saleh, Ramy R., et al.
Publicado: (2020) -
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression
por: Shah, Vandna, et al.
Publicado: (2017) -
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019)